Meridian Bioscience

Meridian Bioscience Free Cash Flow

The Free Cash Flow (FCF) of Meridian Bioscience (VIVO) as of Oct 27, 2026 is 73.75 M USD. In the previous year, Free Cash Flow (FCF) was 48.55 M USD — a change of 51.89% (higher).

Free Cash Flow

73.75 MUSD

YoY

51.89%

Last updated:

Free Cash Flow (FCF) of Meridian Bioscience is 2022 73.75 M USD. Free Cash Flow (FCF) of Meridian Bioscience was 2021 48.55 M USD. It decreases by 51.89% higher compared to the previous year.

The Meridian Bioscience Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2015
38.05 M USD
Jan 1, 2016
33.22 M USD
Jan 1, 2017
36.89 M USD
Jan 1, 2018
30.58 M USD
Jan 1, 2019
32.38 M USD
Jan 1, 2020
44.68 M USD
Jan 1, 2021
48.55 M USD
Jan 1, 2022
73.75 M USD
The Meridian Bioscience Free Cash Flow history
YEARFree Cash FlowYoY
73.75 MUSD+51.89%
48.55 MUSD+8.67%
44.68 MUSD+37.99%
32.38 MUSD+5.89%
30.58 MUSD-17.10%
36.89 MUSD+11.05%
33.22 MUSD-12.69%
38.05 MUSD+21.72%
31.26 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Free Cash Flow (FCF) of Meridian Bioscience is 73.75 M USD in 2022.

Free Cash Flow (FCF) of Meridian Bioscience changed from 48.55 M USD to 73.75 M USD, representing a 51.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Meridian Bioscience

All Key Metrics — Meridian Bioscience